Literature DB >> 2557900

Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex.

R K Andrews1, W J Booth, J J Gorman, P A Castaldi, M C Berndt.   

Abstract

Interaction of von Willebrand factor (vWF) with its platelet receptor only occurs in vitro in the presence of a modulator such as ristocetin. We have recently confirmed that the human platelet membrane glycoprotein (GP) Ib-IX complex is the receptor involved in the ristocetin-dependent binding of vWF by reconstitution with the purified components [Berndt, M.C., Du, X., & Booth, W.J. (1988) Biochemistry 27, 633-640]. We have now developed a similar solid-phase reconstitution assay using an alternate modulator, botrocetin, for the competitive analysis of functional domains in both vWF and the GP Ib-IX complex. Botrocetin was purified from Bothrops jararaca venom by ammonium sulfate fractionation and subsequent DEAE-cellulose and hydroxylapatite chromatography. The purified protein was a 25-kilodalton (kDa) disulfide-linked dimer with apparent subunit molecular weights of 14,000 and 14,500. Binding studies with immobilized botrocetin demonstrated that botrocetin bound to vWF and to a 52/48-kDa region of vWF that contains the GP Ib binding domain, but not to glycocalicin, a proteolytic fragment of GP Ib that contains the vWF binding site. Binding of 125I-labeled vWF to GP Ib-IX complex coated beads and to platelets was strictly botrocetin-dependent with half-maximal binding at a botrocetin concentration of congruent to 0.27 microM. Botrocetin-dependent binding of vWF was specific, saturable, and comparable to that observed with ristocetin. An anti-vWF monoclonal antibody, 3F8, inhibited ristocetin- but not botrocetin-dependent binding of vWF, suggesting the presence of distinct ristocetin and botrocetin modulator sites on vWF. The botrocetin reconstitution assay was at least an order of magnitude more sensitive than the corresponding ristocetin assay for the competitive analysis of functional domains on both vWF and the GP Ib-IX complex and has confirmed the localization of the vWF-binding domain to the 45-kDa N-terminal region of GP Ib.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557900     DOI: 10.1021/bi00447a009

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  22 in total

1.  Increased thrombin responsiveness in platelets from mice lacking glycoprotein V.

Authors:  V Ramakrishnan; P S Reeves; F DeGuzman; U Deshpande; K Ministri-Madrid; R B DuBridge; D R Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

2.  Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease.

Authors:  J L Miller; D Cunningham; V A Lyle; C N Finch
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

3.  Primary structure of two-chain botrocetin, a von Willebrand factor modulator purified from the venom of Bothrops jararaca.

Authors:  Y Usami; Y Fujimura; M Suzuki; Y Ozeki; K Nishio; H Fukui; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

4.  Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.

Authors:  Junling Liu; Malinda E Fitzgerald; Michael C Berndt; Carl W Jackson; T Kent Gartner
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

5.  Vwf K1362A resulted in failure of protein synthesis in mice.

Authors:  Naomi Sanda; Nobuaki Suzuki; Atsuo Suzuki; Takeshi Kanematsu; Mayuko Kishimoto; Hidetoshi Hasuwa; Akira Takagi; Tetsuhito Kojima; Tadashi Matsushita; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2018-02-01       Impact factor: 2.490

6.  A functional 14-3-3zeta-independent association of PI3-kinase with glycoprotein Ib alpha, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex.

Authors:  Fi-Tjen Mu; Robert K Andrews; Jane F Arthur; Adam D Munday; Susan L Cranmer; Shaun P Jackson; Frank C Stomski; Angel F Lopez; Michael C Berndt
Journal:  Blood       Date:  2008-02-25       Impact factor: 22.113

7.  Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.

Authors:  V H Flood; K D Friedman; J C Gill; P A Morateck; J S Wren; J P Scott; R R Montgomery
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

8.  The collagen-binding integrin α2β1 is a novel interaction partner of the Trimeresurus flavoviridis venom protein flavocetin-A.

Authors:  Franziska T Arlinghaus; Johannes A Eble
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

9.  von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.

Authors:  I Rabinowitz; E A Tuley; D J Mancuso; A M Randi; B G Firkin; M A Howard; J E Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  Differential roles for the adapters Gads and LAT in platelet activation by GPVI and CLEC-2.

Authors:  C E Hughes; J M Auger; J McGlade; J A Eble; A C Pearce; S P Watson
Journal:  J Thromb Haemost       Date:  2008-09-27       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.